Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Syndax Pharmaceuticals (SNDX) Leases (2019 - 2025)

Syndax Pharmaceuticals has reported Leases over the past 7 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Leases at $1.3 million for Q4 2025, down 35.71% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (down 35.71% YoY), and the annual figure for FY2025 was $1.3 million, down 35.71%.
  • Leases for Q4 2025 was $1.3 million at Syndax Pharmaceuticals, down from $1.5 million in the prior quarter.
  • Over the last five years, Leases for SNDX hit a ceiling of $2.0 million in Q4 2024 and a floor of $338000.0 in Q2 2021.
  • Median Leases over the past 5 years was $1.1 million (2021), compared with a mean of $1.2 million.
  • Biggest five-year swings in Leases: soared 238.97% in 2021 and later plummeted 56.33% in 2024.
  • Syndax Pharmaceuticals' Leases stood at $983000.0 in 2021, then rose by 5.7% to $1.0 million in 2022, then skyrocketed by 43.12% to $1.5 million in 2023, then skyrocketed by 35.98% to $2.0 million in 2024, then plummeted by 35.71% to $1.3 million in 2025.
  • The last three reported values for Leases were $1.3 million (Q4 2025), $1.5 million (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.